research Patient Perspectives Regarding Artificial Intelligence-Driven Trichoscopy for Alopecia Evaluation
Patients found AI helpful for alopecia diagnosis but want it to support, not replace, doctors.
Search
forLearn
0 / 0 results — no results
Research
5 / 5 resultsresearch Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.
research Exploring Novel Management Options for Alopecia Areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research A Decade of Autologous Micrografting Technology in Hair Restoration: A Review of Clinical Evidence and the Evolving Landscape of Regenerative Treatments
Autologous Micrografting Technology effectively improves hair growth and is a safe, promising option for hair restoration.
research Universal Dermatology: Bridging Gaps in Skin Health
Inclusive dermatology aims to provide personalized skin care for all by addressing diverse needs and disparities.
Community Join
5 / 26 resultscommunity Veradermics is now public with a billion dollar market cap.
Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.
community A positive thought rolling into Christmas
The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.
community Upcoming New Treatments - Based on Phase
Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.
community Pelage are starting phase 3 for PP405 towards the end of 2026
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.